TRIO-US B-12 TALENT

Phase II, Multicenter, Open-Label, 3-Arm Trial to Evaluate the Safety and Efficacy of Trastuzumab Deruxtecan (T-DXd) Alone, with Anastrozole, or in Sequence with Chemotherapy for HER2 Low Hormone Positive (HR+) Breast Cancer in the Neoadjuvant Setting